ALLO
Quality Rating
Allogene Therapeutics, Inc. (ALLO) operates in its industry with a focus on biotechnology R&D as inferred from available data. The company passes debt and income ratio screens but fails liquidity thresholds across all standards due to high cash holdings of 91.4% of market cap. Business activities appear permissible with no identified non-compliant revenue. However, exclusion from all major Shariah indices results in an overall non-compliant status. Investors should monitor cash deployment for potential future compliance.
Purification Required
Moderate purification required - consider carefully
Index Inclusion
Not included in S&P Dow Jones Shariah Indices, MSCI Islamic Indices, FTSE Shariah Indices, or Dow Jones Islamic Market (DJIM)
Key Compliance Considerations
- Liquidity ratio of 91.4% exceeds 30-33% thresholds across AAOIFI, MSCI, and S&P standards
Debt Ratio
26.5%
Liquidity Ratio
91.4%
Interest Income Ratio
1.6%
Purification
1.63%